BioSpace News Archive

Ordaōs partners with NonExomics to create customized mini-proteins.

The plan, worth €30 million, will be implemented over the following two-year period, with the aim of significantly expanding the capacity and expertise of the Settimo Torinese Biotech Hub.

Castor today announced the appointment of Andrew Sadler as Chief Product & Technology Officer (CPTO).

Alumis Inc. today announced that the first patient has been dosed in Stride, a Phase 2 clinical trial of ESK-001 for the treatment of patients with moderate to severe plaque psoriasis. ESK-001 is a highly selective and potentially best in class allosteric tyrosine kinase 2 (TYK2) inhibitor.

Ironshore Therapeutics Inc. today announced the appointments of Lewis Warrington as Chief Medical Officer, Nelson F. Isabel as Chief Financial Officer, Nilay Patel as Chief Legal Officer and Tim Branz as Chief Information Officer.

FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO ® Admixture to 96 Hours Following Reconstitution.

Unlearn®, the only artificial intelligence (AI) company developing prognostic digital twins to run smaller, faster clinical trials, today announced that the European Medicines Agency (EMA) has released its final favorable qualification opinion providing a regulatory framework for the application of the company’s TwinRCT™ solution in Phase 2 and 3 clinical trials.

bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company’s September 6, 2022, public offering of securities.

Sight Sciences, Inc., announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI Surgical System as a standalone minimally invasive glaucoma surgery during this year’s annual AAO convention at McCormick Place in Chicago, IL.

Citius Pharmaceuticals, Inc. today announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denileukin diftitox (I/ONTAK), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).